- Home
- ACIC vs ARCT Comparison
ACIC vs ARCT Comparison
Compare ACIC & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- ARCT
- Stock Information
- Founded
- ACIC 1999
- ARCT 2013
- Country
- ACIC United States
- ARCT United States
- Employees
- ACIC N/A
- ARCT N/A
- Industry
- ACIC Property-Casualty Insurers
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- ARCT Health Care
- Exchange
- ACIC Nasdaq
- ARCT Nasdaq
- Market Cap
- ACIC 644.2M
- ARCT 602.7M
- IPO Year
- ACIC N/A
- ARCT N/A
- Fundamental
- Price
- ACIC $13.46
- ARCT $16.91
- Analyst Decision
- ACIC Buy
- ARCT Strong Buy
- Analyst Count
- ACIC 1
- ARCT 7
- Target Price
- ACIC $16.00
- ARCT $65.00
- AVG Volume (30 Days)
- ACIC 194.3K
- ARCT 478.9K
- Earning Date
- ACIC 11-06-2024
- ARCT 11-07-2024
- Dividend Yield
- ACIC N/A
- ARCT N/A
- EPS Growth
- ACIC N/A
- ARCT N/A
- EPS
- ACIC 1.76
- ARCT N/A
- Revenue
- ACIC $290,784,000.00
- ARCT $160,399,000.00
- Revenue This Year
- ACIC N/A
- ARCT $13.02
- Revenue Next Year
- ACIC $12.98
- ARCT $5.58
- P/E Ratio
- ACIC $7.67
- ARCT N/A
- Revenue Growth
- ACIC 1.02
- ARCT N/A
- 52 Week Low
- ACIC $8.10
- ARCT $14.93
- 52 Week High
- ACIC $14.38
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- ACIC 62.95
- ARCT 41.60
- Support Level
- ACIC $12.70
- ARCT $15.50
- Resistance Level
- ACIC $13.31
- ARCT $18.09
- Average True Range (ATR)
- ACIC 0.49
- ARCT 1.51
- MACD
- ACIC -0.01
- ARCT -0.10
- Stochastic Oscillator
- ACIC 96.05
- ARCT 29.64
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary. The company has two segments namely: Commercial Lines Business and Personal Lines Business. It derives maximum revenue from Commercial Lines Business Segment.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.